Cargando…

A Novel Dipeptidyl Peptidase-4 Inhibitor DA-1229 Ameliorates Tubulointerstitial Fibrosis in Cyclosporine Nephrotoxicity in Mice

Cyclosporine A (CyA) is an immunosuppressive agent that induces nephrotoxicity with long-term treatment. The roles of DPP-4 and its inhibitors in cyclosporine nephrotoxicity are not fully understood. Therefore, we investigated the effects of a novel DPP-4 inhibitor, DA-1229, on the progression of re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Hye Sook, Lee, Ji Eun, Ghee, Jung Yeon, Kang, Young Sun, Cha, Jin Joo, Han, Jee Young, Han, Sang Youb, Cha, Dae Ryong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003165/ https://www.ncbi.nlm.nih.gov/pubmed/33803842 http://dx.doi.org/10.3390/life11030251

Ejemplares similares

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
por: Gu, Namyi, et al.
Publicado: (2014)

PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis
por: Han, Jee-Young, et al.
Publicado: (2010)

SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes
por: Han, Sang Youb, et al.
Publicado: (2023)

Upregulation of VSIG4 in Type 2 Diabetic Kidney Disease
por: Han, Sang Youb, et al.
Publicado: (2022)

The Role of V-Set Ig Domain-Containing 4 in Chronic Kidney Disease Models
por: Han, Sang Youb, et al.
Publicado: (2023)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Methotrexate and Cyclosporine Treatments Modify the Activities of Dipeptidyl Peptidase IV and Prolyl Oligopeptidase in Murine Macrophages
por: Olivo, R. A., et al.
Publicado: (2008)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
por: Choi, Seung Hee, et al.
Publicado: (2017)

Activation of Intrarenal Complement System in Mouse Model for Chronic Cyclosporine Nephrotoxicity
por: Kim, Young Ok, et al.
Publicado: (2007)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Effect of Fosfomycin on Cyclosporine Nephrotoxicity
por: Ortega-Trejo, Juan Antonio, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
por: Lee, Minyoung, et al.
Publicado: (2020)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Agonism of Prostaglandin E2 Receptor 4 Ameliorates Tubulointerstitial Injury in Nephrotoxic Serum Nephritis in Mice
por: Aringer, Ida, et al.
Publicado: (2021)

Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
por: Cha, Jin Joo, et al.
Publicado: (2012)

Effect of IgA Aggregates on Transforming Growth Factor-β1 Production in Human Mesangial Cells and the Intraglomerular Expression of Transforming Growth Factor-β1 in Patients with IgA Nephropathy
por: Han, Sang-Youb, et al.
Publicado: (2005)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
por: Joo, Kwon Wook, et al.
Publicado: (2013)

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
por: Bae, Jaehyun, et al.
Publicado: (2016)

Dipeptidyl Peptidase 10, a Novel Prognostic Marker in Colorectal Cancer
por: Park, Heae Surng, et al.
Publicado: (2013)

Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis
por: Park, Se Hee, et al.
Publicado: (2016)

Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
por: Iwakura, Takamasa, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis
por: Lee, Sahmin, et al.
Publicado: (2020)

Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation
por: Han, Ruijun, et al.
Publicado: (2015)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis
por: Shiheido-Watanabe, Yuka, et al.
Publicado: (2021)

Effect of Erdosteine on Cyclosporine Induced Chronic Nephrotoxicity
por: Briguori, Carlo, et al.
Publicado: (2012)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

Serum interferon-γ and urinary monocyte chemoattractant peptide-1 are important factors in the pathogenesis of immunoglobulin A nephropathy
por: Han, Sang Youb, et al.
Publicado: (2021)

Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension
por: Cappetta, Donato, et al.
Publicado: (2019)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
por: Torrecillas-Baena, Bárbara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9e1v62poaja8kro4lpf20ht73v